Community oncology faces significant challenges from the Inflation Reduction Act's (IRA) drug pricing changes, risking ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced st ...

Ozempic (semaglutide) is an injectable medication ... including government-related coverage such as Medicare Supplement Plans, as these do not typically cover the cost of GLP-1 medications.

In the United States, prescriptions for weight-loss drugs for teens have increased 600 per cent, according to one study. But ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies ...

Rybelsus contains the active ingredient semaglutide. It belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist drug class. (A drug class is a group of medications that work in a similar way.) ...

What is the difference between prediabetes and diabetes, and which do I have? I am male, 85 years old, 170 pounds, and 6 feet ...

What is it? A medication called semaglutide, which is sold under different brand names, including Ozempic, approved in 2017 for treating type 2 diabetes, and Wegovy, approved just last year for ...

Spending on care: Aflac spends much more on member benefits and less on overhead than the average Medicare Supplement Insurance company. Complaints: Aflac members file complaints about their ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

The price of Wegovy, Novo Nordisk’s blockbuster weight-loss drug, is $1,349 a month in the U.S.; in Germany, it’s $328. The U.S. price for Keytruda, a cancer treatment, is $191,000 ...